Gilead Sciences (GILD)
Shares of the biopharmaceutical firm dove 14% on news that study results showed that a two-drug regime that includes Gilead’s experimental GS-7977 failed to suppress the hepatitis C virus in six of 10 difficult-to-treat patients. Writing in Barron’s Take, Johanna Bennett noted, “For investors willing to stomach some risk, we think Gilead offers a buying opportunity.” (See “Is Battered Gilead a Buy?”)
…